Evidence map›Paper›PMID 35008426›Full record

ArticleCancers2022

Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (GBM) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures.

Ntlotlang Mokgautsi, Yu-Cheng Kuo, Sung-Ling Tang, Feng-Cheng Liu, Shiang-Jiun Chen, Alexander T H Wu, Hsu-Shan Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Investigation ofIn silico pharmacology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ntlotlang MokgautsiPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.ORCID 0000-0003-2076-9768
Yu-Cheng KuoDepartment of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Sung-Ling TangDepartment of Pharmacy Practice, Tri-Service General Hospital, School of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan.
Feng-Cheng LiuDepartment of Rheumatology/Immunology and Allergy, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Neihu Dist., Taipei City 114, Taiwan.
Shiang-Jiun ChenSchool of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan.
Alexander T H WuGraduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0002-0178-6530
Hsu-Shan HuangPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.ORCID 0000-0001-6193-5182
Taipei Medical University · TWTri-Service General Hospital · TWChina Medical University · TWNational Defense Medical Center · TWTaipei Medical University Hospital · TW

Funding

Ministry of Education, Taipei Medical University TAIWAN DP2-110-21121-01-H-03-03Ministry of Science and Technology MOST 109-2113-M- 038-003 and MOST 110-2314-B-038-120
6 · The paper itself

Abstract

Current anticancer treatments are inefficient against glioblastoma multiforme (GBM), which remains one of the most aggressive and lethal cancers. Evidence has shown the presence of glioblastoma stem cells (GSCs), which are chemoradioresistant and associated with high invasive capabilities in normal brain tissues. Moreover, accumulating studies have indicated that radiotherapy contributes to abnormalities in cell cycle checkpoints, including the G

Indexed as

bioinformaticschemoradioresistancegenetic heterogeneityglioblastoma multiforme (GBM)molecular dockingNational Cancer Institute (NCI)-60temozolomide (TMZ)

Identifiers

PMID35008426
PMCPMC8750065
OpenAlexW4206202481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.